The groundbreaking rise of Viagra has consistently remained a example of pharmaceutical success, yet its legacy within the broader sector now triggers questions about future gains. Alternative versions are undercutting market share, leading to worries that betting on companies heavily reliant to Viagra's once-dominant standing could be a dangerous